What Constitutes a Positive ANA and When to Refer to Rheumatology
An ANA titer ≥1:160 by indirect immunofluorescence (IIFA) on HEp-2 cells is considered positive, but referral to rheumatology should be based primarily on clinical suspicion of systemic autoimmune rheumatic disease (SARD), not the ANA result alone. 1
Defining a Positive ANA
The international consensus establishes that:
- Screening dilution of 1:160 is the standard threshold for adults, representing the 95th percentile of healthy controls 1
- At 1:40 dilution, 31.7% of healthy subjects test positive; at 1:80,13.3% are positive; at 1:160, only 5.0% are positive 1
- IIFA on HEp-2 cells is the reference standard method for ANA screening 1
- Both the titer AND pattern should be reported when positive 1
Critical caveat: Low-titer ANA (1:40-1:80) may still be clinically significant in the right context, though titres above the screening threshold have no bearing on diagnosis or disease activity 1. Conversely, even high-titer ANA (≥1:320) does not guarantee SARD—only 35% of patients with such titers actually had connective tissue disease in one study 2.
When to Refer to Rheumatology
The decision to refer should be driven by clinical features suggestive of SARD, not by ANA positivity alone. The evidence is stark on this point:
Do NOT Refer Based Solely On:
- Isolated positive ANA without clinical symptoms 3, 4
- Widespread pain as the only symptom (the most common inappropriate reason for ANA testing) 3
- ANA titers <1:160 in the absence of clinical findings—no SARD was identified in this group 3
DO Refer When ANA-Positive AND:
High-priority clinical scenarios:
- Malar rash, photosensitivity, oral ulcers, serositis (suggestive of SLE)
- Raynaud phenomenon with skin thickening (suggestive of systemic sclerosis)
- Dry eyes/mouth with parotid swelling (suggestive of Sjögren syndrome)
- Proximal muscle weakness with elevated creatine kinase (suggestive of myositis)
- Unexplained cytopenias (thrombocytopenia, leukopenia, hemolytic anemia)
- Unexplained proteinuria or active urinary sediment
- Inflammatory arthritis (especially symmetric small joint involvement)
- Interstitial lung disease (particularly with anti-Ro52, anti-SS-A, or anti-Scl-70 positivity) 5
Specific ANA patterns that warrant closer attention:
- Nucleolar pattern: Independently associated with pulmonary complications, particularly interstitial lung disease 6
- Homogeneous or mixed patterns: More frequent in confirmed rheumatologic diagnoses 7
- Anti-centromere pattern: Associated with limited systemic sclerosis
- Rim/peripheral pattern: Associated with SLE
The Sobering Reality of ANA Testing
The positive predictive value of ANA testing is dismally low when ordered inappropriately:
- In one tertiary care study, only 9.1% of patients referred for positive ANA had any SARD, and only 2.1% had lupus 3
- 83.6% of ANA-positive patients had no rheumatologic diagnosis 7
- More than 90% of patients referred to rheumatology for isolated positive ANA had no evidence of ANA-associated rheumatic disease 3
- Even among patients with ANA titers ≥4 dilutions above screening, 29% had no CTD diagnosis 2
The fundamental problem: ANA testing has minimal clinical significance in the absence of connective tissue disease symptoms 4. The poor predictive value is attributable to unnecessary testing in patients with low pretest probability 3.
Practical Algorithm for Primary Care
Before ordering ANA: Ask yourself if the patient has specific clinical features of SARD (see list above). If not, don't order it.
If ANA is positive at ≥1:160:
- Review for any clinical features of SARD
- Check complete blood count (for cytopenias)
- Check urinalysis (for proteinuria/active sediment)
- Note the ANA pattern
Refer to rheumatology if:
- Any clinical features of SARD are present, OR
- Unexplained cytopenias or proteinuria, OR
- Nucleolar pattern (due to pulmonary risk)
Do NOT refer if:
- Isolated positive ANA with no clinical features
- Only symptom is widespread pain or fatigue
- ANA <1:160
Special consideration: If clinical suspicion for SARD is high but alternative methods (ELISA, multiplex) are negative, IIFA must be performed as false negatives can occur with non-IIFA methods 1
Additional Testing After Positive ANA
When ANA is positive and clinical suspicion exists, reflex testing for specific antibodies should follow based on pattern and clinical context 1:
- If clinical suspicion of SLE: anti-dsDNA antibodies (by Farr assay or CLIFT for high specificity) 1
- Based on pattern/clinical context: anti-ENA panel (anti-Ro/SS-A, anti-La/SS-B, anti-Sm, anti-RNP, anti-Scl-70, anti-Jo-1) 1
- For ILD patients: Anti-Ro52, anti-SS-A, and anti-Scl-70 capture 68.3% of CTD-ILD cases 5
Important: Anti-DFS70 antibodies (present in ~15% of ANA-positive sera) are associated with absence of SARD in 91.2% of cases and may represent a "healthy ANA" 8.
The bottom line: ANA is a screening test that requires clinical context for interpretation—it should never be the sole basis for rheumatology referral 1, 4.